Quick Takeaways
- AbbVie Inc. filed SCHEDULE 13G for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 9%.
- Date of event: 11 Feb 2025.
AbbVie Inc. - 11 Feb 2025 SCHEDULE 13G Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)
- Filing Manager
- AbbVie Inc.
- Reporting Manager
- AbbVie Inc.
- Symbol
- XLO
- Shares outstanding
- 48,309,178 shares
- Disclosed Ownership
- 4,347,826 shares
- Ownership
- 9%
- Form type
- SCHEDULE 13G
- Filing time
- 18 Feb 2025, 16:15:26 UTC
- Date of event
- 11 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"AbbVie Inc. disclosed 9% ownership in Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO) on 11 Feb 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 18 Feb 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 9% | 4,347,826 | 4,347,826 | 0 | /s/ Scott T. Reents | Scott T. Reents, Executive Vice President, Chief Financial Officer |